MILANESI, NICOLA
 Distribuzione geografica
Continente #
AS - Asia 78
NA - Nord America 59
EU - Europa 48
Continente sconosciuto - Info sul continente non disponibili 6
AF - Africa 2
SA - Sud America 2
OC - Oceania 1
Totale 196
Nazione #
US - Stati Uniti d'America 51
IT - Italia 39
BD - Bangladesh 31
CN - Cina 18
JP - Giappone 9
SG - Singapore 8
VN - Vietnam 6
CA - Canada 4
FR - Francia 4
JM - Giamaica 3
NL - Olanda 2
AL - Albania 1
AR - Argentina 1
AU - Australia 1
BR - Brasile 1
DE - Germania 1
EG - Egitto 1
GB - Regno Unito 1
HK - Hong Kong 1
IN - India 1
KE - Kenya 1
KR - Corea 1
PK - Pakistan 1
TR - Turchia 1
TT - Trinidad e Tobago 1
UZ - Uzbekistan 1
Totale 190
Città #
Rome 15
Tokyo 9
Ashburn 8
Council Bluffs 7
Buffalo 6
Milan 6
Los Angeles 3
Santa Clara 3
Florence 2
Genoa 2
Kingston 2
Palermo 2
Paris 2
San Jose 2
Abū Kabīr 1
Aci Catena 1
Amsterdam 1
Bahawalpur 1
Bengaluru 1
Boardman 1
Bình Phước 1
Bảo Lộc 1
Cairo 1
Camaiore 1
Cardiff 1
Dallas 1
East Lansing 1
Edmonds 1
Edmonton 1
Frankfurt am Main 1
Front Royal 1
Garland 1
Gaziantep 1
Gravina in Puglia 1
Guoyuan Xincun 1
Hanoi 1
Hong Kong 1
Huế 1
Jersey City 1
Las Toscas 1
Lethbridge 1
Lincoln 1
Loomis 1
Mascalucia 1
Milwaukee 1
Montego Bay 1
Montreal 1
New York 1
Olympia 1
Padua 1
Perth 1
Port of Spain 1
Porto Alegre 1
Prescott 1
Quận Ba 1
Riardo 1
Roanoke 1
Rocca di Papa 1
Seodaemun-gu 1
Singapore 1
Tashkent 1
Tirana 1
Toronto 1
Totale 118
Nome #
Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective Study 53
Efficacy of risankizumab after intra-class switching between anti IL-23 antagonists: a multi-center, retrospective, real-life observation 48
Risankizumab in Oncologic Patients With Psoriasis: A Case Series 29
Long-term drug survival of risankizumab in psoriasis: insights from a real-life multicenter study on hard-to-treat areas 25
Risankizumab in very elderly patients in real-world practice 23
Real‐life effectiveness of Risankizumab according to body mass index: Results of an Italian multicentre retrospective study 18
Totale 196
Categoria #
all - tutte 520
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 520


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2025/2026189 0 0 0 0 0 0 0 13 55 30 38 53
2026/20277 7 0 0 0 0 0 0 0 0 0 0 0
Totale 196